Table 1. Patient and Tumor Characteristics.

Characteristic	Total		BRCA Mutant		BRCA Wild Type		p-value
	N	%	N	%	N	%
	77	100%	15	19.5%	62	80.5%	--
Age at Diagnosis
Median	51	(27-83)	45	(27-61)	53	(28-83)	0.0051
Race
Black	18	23.37%	2	13.33%	16	25.81%
Hispanic	8	10.38%	3	20.00%	5	8.06%
White	50	64.93%	10	66.67%	40	64.52%
Other	1	1.29%	0	0.00%	1	1.61%	0.4385
Menopausal Status
Pre-menopausal	29	37.66%	8	53.33%	21	33.87%
Post-menopausal	48	62.33%	7	46.67%	41	66.13%	0.2718
Histology
Ductal	64	83.11%	12	80.00%	52	83.87%
Other	13	16.88%	3	20.00%	10	16.13%	0.7096
Pathological Stage
I and II	47	61.03%	8	53.33%	39	62.90%
III	30	38.96%	7	46.67%	23	37.10%	0.6988
Nuclear Grade
2	5	6.49%	2	13.33%	3	4.84%
3	70	90.90%	13	86.67%	57	91.94%	0.2598
Lymphovascular Invasion
Positive	18	23.37%	3	20.00%	15	24.19%
Negative	57	74.02%	12	80.00%	45	72.58%	1.0
Adjuvant Chemotherapy
Anthracycline-based	1	1.3%	1	6.7%	0	0%
Anthracycline/Taxane-based	75	97.4%	13	86.7%	62	100%
None	1	1.3%	1	6.7%	0	0%	0.036
Adjuvant Radiotherapy
Yes	42	54.5%	8	53.3%	34	54.8%
No	35	45.5%	7	64.7%	28	45.2%	0.91
Surgery Type
Breast Conservation	25	32.5%	3	20%	22	35.5%
Mastectomy	52	67.5%	12	80%	40	64.5%	0.36
Contralateral Prophylactic Mastectomy
Yes	10	13%	5	33.3%	5	8.1%
No	67	87%	10	66.7%	57	91.9%	0.02